Shun-ying Hu

Learn More
The influence of glucagon-like peptide-1 has been studied in several studies in patients with acute myocardial infarction, but not in patients with non-ST-segment elevation myocardial infarction (NSTEMI). We planned to evaluate the effects of liraglutide on left ventricular function in patients with NSTEMI. A total of 90 patients were randomized 1:1 to(More)
OBJECTIVE This study aimed to determine the prevalence rates of conventional risk factors and to analyze the features of coronary lesions in patients with coronary heart disease (CHD). METHODS 3765 CHD cases were collected from the General Hospital of PLA in Beijing from 2009 to 2010 (2661 men, 1104 women). All the CHD patients enrolled in our study were(More)
BACKGROUND Liraglutide is glucagon-like peptide-1 receptor agonist for treating patients with type 2 diabetes mellitus. Our previous studies have demonstrated that liraglutide protects cardiac function through improving endothelial function in patients with acute myocardial infarction undergoing percutaneous coronary intervention. The present study will(More)
OBJECTIVE To investigate the effect of liraglutide, an analogue of glucagon-like peptide-1, on the proliferation and migration of cardiac microvascular endothelial cells (CMECs) and explore the mechanism. METHODS In vitro cultured CMECs of SD rats were purified by differential adhesion method and identified immunocytochemically using CD31 antibody and(More)
  • 1